A little-noticed provision in a bill recently passed by Congress would make it harder for drug makers to strike so-called pay-to-delay deals that could prevent biosimilar medicines from reaching the market and lowering U.S. health care costs.
Tucked into the Patient Right to Know Act is language that would require companies that make biologics and biosimilar medicines to report settlements of patent litigation to the Department of Justice and the Federal Trade Commission. This would allow the agencies to have the same kind of information resulting from settlements pertaining to generic drugs.
How might settlement information given to the feds lower health care costs, though?
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
